Edgewise Therapeutics
EWTX
95 hedge funds and large institutions have $539M invested in Edgewise Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 40 increasing their positions, 23 reducing their positions, and 3 closing their positions.
333% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 3
164% more call options, than puts
Call options by funds: $124K | Put options by funds: $47K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
74% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 23
22% more capital invested
Capital invested by funds: $443M → $539M (+$95.7M)
12% more funds holding
Funds holding: 85 → 95 (+10)
4.77% more ownership
Funds ownership: 105.05% → 109.82% (+4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$8.72M |
| 2 |
Goldman Sachs
New York
|
+$8.43M |
| 3 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$6.01M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$3.31M |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.92M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.68M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.8M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$1.59M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$788K |
EWTX Hedge Fund Activity: Q2 2023 in Review
95 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q2 2023, worth a combined $539M — up 22% from $443M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new EWTX positions and 3 closed out — a net gain of 10 holders — while 40 added to existing stakes and 23 trimmed.
The largest buyer was Viking Global Investors, adding an estimated $8.72M. The largest seller was Fidelity Investments, cutting an estimated $4.92M.
- 95 institutional investors held Edgewise Therapeutics (EWTX) as of Q2 2023, up from 85 in Q1 2023.
- Funds reported $539M of Edgewise Therapeutics stock for Q2 2023, up 22% quarter-over-quarter.
- 13 funds opened new Edgewise Therapeutics positions in Q2 2023 and 3 closed out, a net change of +10 holders.
- The largest Edgewise Therapeutics buyer in Q2 2023 was Viking Global Investors, an estimated $8.72M added.
- The largest Edgewise Therapeutics seller in Q2 2023 was Fidelity Investments, an estimated $4.92M sold.
Based on aggregated 13F filings for Q2 2023.